TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioLife Solutions ( (BLFS) ) has issued an update.
On November 17, 2025, BioLife Solutions released an investor presentation highlighting its financial performance and strategic focus. The company reported a revenue guidance of $95-96 million for fiscal year 2025, with an expected organic revenue growth of 27-29%. BioLife Solutions has successfully refocused its portfolio by divesting non-core assets and targeting acquisitions, which has led to improved profitability and sustainable growth. The presentation also emphasized the company’s involvement in over 950 active global cell-based therapy trials, underscoring its strong market positioning and commitment to innovation in the cell-based therapy industry.
The most recent analyst rating on (BLFS) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.
Spark’s Take on BLFS Stock
According to Spark, TipRanks’ AI Analyst, BLFS is a Neutral.
BioLife Solutions’ overall stock score is driven by a mix of financial challenges and positive earnings call insights. The company’s financial performance is hindered by declining revenues and profitability, but it benefits from a strong gross profit margin and conservative leverage. Technical analysis indicates mixed signals, with short-term bearish momentum but longer-term support. Valuation is a weak point due to significant losses and no dividend yield. However, the positive sentiment from the earnings call, highlighting strong revenue growth and strategic focus, provides a counterbalance, resulting in a moderate overall score.
To see Spark’s full report on BLFS stock, click here.
More about BioLife Solutions
BioLife Solutions is a leading provider of biopreservation and processing tools for cell-based therapies. The company focuses on biopreservation media products like CryoStor® and HypoThermosol®, as well as cell processing tools such as CellSeal® and hPL solutions. BioLife Solutions is committed to advancing and de-risking the development and delivery of cell-based therapies, with a significant presence in the North American market and involvement in numerous clinical trials.
Average Trading Volume: 387,915
Technical Sentiment Signal: Buy
Current Market Cap: $1.16B
See more insights into BLFS stock on TipRanks’ Stock Analysis page.